| Literature DB >> 23662139 |
Hongmei Jia1, Zhiheng Su, Wei Long, Yuetao Liu, Xing Chang, Hongwu Zhang, Gang Ding, Yufei Feng, Dayong Cai, Zhongmei Zou.
Abstract
This study proposed a new strategy for uncovering the active chemical constituents of a traditional Chinese medicines (TCMs) formula, Chaihu-Shu-Gan-San (CSGS). Metabonomics and chemical profile were integrated in combination with the multivariate statistical analysis (MVA) to discover the chemical constituents which contribute to the antidepressant effect of CSGS. Based upon the difference between CSGS and QZ (CSGS without Zhi-Qiao) extracts in the chemical profiles and the regulations of metabolic disturbances induced by CUMS, synephrine, naringin, hesperidin, and neohesperidin were recognized as the active constituents of CSGS from Zhi-qiao responsible for those missing regulations of CSGS when Zhi-Qiao was subtracted from the whole formula. They participated in the regulations of the deviated metabolites 2-4, 10-14, and 22-25, involved in metabolic pathways of ketone bodies synthesis, phenylalanine, tyrosine and tryptophan biosynthesis, valine, aspartate, glutamate metabolism, and glycolysis/gluconeogenesis. Furthermore, the assay of MAO-A activity confirmed the potential antidepressant effect of naringin and its active sites on the MAO-A was inferred by molecular docking study. The integration of metabonomics and chemical profile was proved to be a useful strategy for uncovering what the active chemical constituents in TCM formula are and how they make contributions for the efficacy of the formula.Entities:
Year: 2013 PMID: 23662139 PMCID: PMC3638638 DOI: 10.1155/2013/487158
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The proposed strategy for discovering the active constituents of CSGS responsible for its therapeutic effect on depression.
Figure 2MVA of urine samples from all groups detected by NMR and UPLC-Q-TOF/MS. A1, B1, and C1: the spectra and chromatograms of urine samples. Black color stands for control group, red color for CUMS group, blue color for CSGS treated group, and green color for QZ treated group; A2, B2, and C2. The score plots of control, CUMS, CSGS, and QZ groups; A3, B3, and C3. OPLS-DA scores plots of CUMS versus model groups, CUMS versus CSGS groups, CUMS versus QZ groups (A3: Q2X CUM = 0.879, R 2 Y CUM = 0.998, Q (CUM) 2 = 0.607, B3: Q 2 X (CUM) = 0.604, R 2 Y CUM = 0.994, Q (CUM) 2 = 0.99; C3: Q 2 X (CUM) = 0.659, R 2 Y CUM = 0.999, Q (CUM) 2 = 0.999); A4, B4, and C4: line plots, S-plots, and VIP-value plots of urine samples detected by NMR and UPLC-Q-TOF/MS, respectively.
The potential biomarkers of CUMS-induced depression and their variation tendency after oral administration of CSGS or QZ extract for 28 days.
| NMR | UPLC-Q-TOF/MS | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Metabolites |
| Trend | No. | Metabolites | TR |
| Selected ion | Elemental composition | Fragment of MS/MS | Trend | ||||
| CUMSc | CSGSd | QZd | CUMSc | CSGSd | QZd | ||||||||||
| 1 | Lipid(CH3CH2) | 0.94 (t) | ↓** | ↑** | ↑** | 15 | Dopaminea | 1.07 | 154.1628 | [M+H]+ | C8H11NO2 | 154.1628; 119.1435; 109.1635; 91.1547 | ↑** | ↓** | ↓** |
| 2 | Isoleucine | 0.94 (t) | ↓** | ↑** | ↑ | 16 | Histamineb | 0.7 | 112.0727 | [M−H]− | C5H9N3 | 112.0727; 95.0653 | ↑** | ↓** | ↓** |
| 3 | Glutamate | 2.36 (m) | ↓** | ↑** | ↑ | 17 | Isobutyrylglycineb | 1.15 | 144.1583 | [M−H]− | C6H11NO3 | 128.2656; 74.1324 | ↑** | ↓** | ↓** |
| 4 | L-dopa | 2.96 (d) | ↓** | ↑** | ↑ | 18 | 2-phenylethanol glucuronideb | 5.94 | 297.0976 | [M−H]− | C14H18O7 | ND | ↑** | ↓** | ↓** |
| 5 |
| 3.86 (dd), 5.23 (d) | ↑** | ↓** | ↓** | 19 | 3-hydroxyhippuric acida | 4.36 | 195.1846 | [M+H]+ | C9H9NO4 | 195.1846; 180.0856 | ↓** | ↑** | ↑** |
| 6 | L-serine | 3.96 (d) | ↑** | ↓** | ↓** | 20 | Creatinea | 4.36 | 132.0951 | [M+H]+ | C4H9N3O2 | 132.0951; 90.1743 | ↓** | ↑** | ↑** |
| 7 | Phenylalanine | 3.97, 7.32 (m) | ↑** | ↓** | ↓** | 21 | 5-aminoimidazole-4-carboxamideb | 2.93 | 125.0874 | [M−H]− | C4H6N4O | ND | ↓** | ↑** | ↑** |
| 8 | Hippurate acid | 7.55 (m), 7.57 (m), 7.84 (d) | ↑** | ↓** | ↓** | 22 | Glyceric acid 1,3-biphosphatea | 0.59 | 267.0585 | [M+H]+ | C3H8O10P2 | 267.0585; 250.0323 | ↓** | ↑** | — |
| 9 | Kynurenic acid | 7.64 (d) | ↑** | ↓** | ↓** | 23 | L-kynureninea | 0.64 | 209.0795 | [M+H]+ | C10H12N2O3 | 209.0795; 192.1320; 94.3122 | ↓** | ↑** | — |
| 10 | Acetoacetate | 2.22 (s) | ↓** | ↑** | — | 24 | 2-aminomuconate semialdehydeb | 9.29 | 140.1169 | [M−H]− | C6H7NO3 | ND | ↓** | ↑** | — |
| 11 | 3-hydroxybutyrate | 2.31 (d), 2.33 (m), 2.38 (m) | ↓** | ↑** | — | 25 | 2-amino-3-carboxymuconate semialdehydeb | 9.69 | 184.1278 | [M−H]− | C7H7NO5 | ND | ↓** | ↑** | — |
| 12 | Pyruvate | 2.36 (s) | ↓** | ↑** | — | 26 | N-acetylserotoninb | 4.68 | 217.1081 | [M−H]− | C12H14N2O2 | ND | ↓** | — | ↑** |
| 13 | Glutamine | 2.08 (m) | ↓** | ↑** | — | 27 | Indole-3-ethanola | 3.37 | 162.1183 | [M+H]+ | C10H11NO | 162.1183; 144.1054 | ↑** | — | ↓** |
| 14 | Tyrosine | 7.22 (m) | ↑** | ↓** | — | 28 | 5-methoxytryptaminea | 1.26 | 191.0824 | [M+H]+ | C11H14N2O | 191.0824; 173.0807; 160.097 | ↑** | — | ↓** |
aThe potential biomarkers were detected by UPLC-Q-TOF/MS in positive mode.
bThe potential biomarkers were detected by UPLC-Q-TOF/MS in negative mode.
cChang trend compared to control group.
dChang trend compared to CUMS group.
The levels of potential biomarkers were labeled with (↓) downregulated and (↑) upregulated (*P < 0.05; **P < 0.01); (—) represents no statistically significant difference.
CUMS: model group; CSGS: CSGS treated group with CUMS; QZ: QZ treated group with CUMS.
Figure 3(a) Urinary metabolic pathways of CUMS-induced depression with CSGS or QZ treatment. Metabolites in red font: the potential biomarkers on which CSGS had regulations but QZ did not; metabolites in blue font: the potential biomarkers on which QZ had regulations but CSGS did not. (b) The levels of 12 potential biomarkers for differentiating CSGS and QZ treated. (*P < 0.05 versus CUMS group, **P < 0.01 versus CUMS group).
Figure 4MVA on chemical profiles of the CSGS and QZ extracts. (a) Score plots in OPLS-DA analysis of CSGS and QZ. (b) Trend plots: the level of the variables in the CSGS (black spot) and QZ extracts (red spot). (c) The structures and MS spectra of synephrine, naringin, and hesperidin/neohesperidin.
Inhibition of synephrine, naringin, hesperidin, and neohesperidin against MAO-A activity.
| No. | Compounds | IC50 ( |
|---|---|---|
| i | Synephrine | 15.23 |
| ii | Naringin | 5.82 |
| iii- | Hesperidin | 26.72 |
| iii- | Neohesperidin | 93.76 |
| Control | Moclobemide | 5.25 |
Figure 5Computer-aided molecular docking. (a) The 2D map of predicted binding orientation of harmine within the MAO-A active site. (b) The 2D map of predicted binding orientation of naringenin within the MAO-A active site. (c) The 3D map of predicted binding mode of naringenin within the active site of MAO-A.